Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott OTCs divested

This article was originally published in The Tan Sheet

Executive Summary

Ross Products parent records $30 mil. in Q4 from sale of Clear eyes eye drops, Murine eye drops and ear care products to Prestige Brands International. Deal was completed Dec. 30, according to Abbott, which says divested brands were profitable but no longer fit its strategic direction. Abbott expressed similar rationale for selling Selsun Blue dandruff shampoo line to Chattem last year (1"The Tan Sheet" March 11, 2002, p. 5). Sales for Ross division, which markets Similac infant formula and Ensure, Glucerna adult nutritionals, rose 3.4% in Q4 to $502 mil. but were flat for the year at $2.09 bil. During Jan. 16 analysts call, Abbott Medical Products Group President & COO Richard Gonzalez announces two "strategic introductions" for adult nutritionals segment in 2003 - Ensure in a plastic, reclosable container, and retail launch of Prosure, a product for weight loss in oncology patients that is currently available in the institutional segment...

You may also be interested in...

Abbott Q1 sales

Abbott Park, Ill.-based firm's Ross Products division's Q1 sales rose 3.8% to $604 mil., despite absence of revenue from Clear eyes eye drops, Murine eye and ear care products, which were divested to Prestige Brands International last quarter (1"The Tan Sheet" Jan. 20, 2003, In Brief). Sales increase likely was due to Ross' introduction of infant formulas fortified with docosahexaenoic acid and arachidonic acid...

Chattem Selsun Blue Purchase Provides Entry Into Five New Foreign Markets

Line extensions and a major marketing push are among the growth tactics Chattem expects to pursue when it brings Selsun Blue into its consumer health portfolio. Chattem has agreed to purchase the anti-dandruff line from Abbott Labs subsidiary Ross Products

Arena Cannabinoid Pain Compound Misses In Phase IIb IBS Trial

Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts